Stock Analiz

MiNK Therapeutics, Inc. INKT

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026

$9.34Market cap $48M
Open the interactive analysis →

MiNK Therapeutics, Inc. (INKT) is a healthcare company listed in the US with a market value of about $48M.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (3/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -94%.

About MiNK Therapeutics

MiNK Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. It was profitable in 0 of the last 6 years in our data. Its share count rose by 27% over three years (dilution for shareholders).

Score: 0.8 / 5

Value0/5
Future growth0/5
Track record1/5
Financial health3/5
Shareholder returns0/5

Checks passed

  • ROE above 15%
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)—
ROIC (5-yr avg.)-94.2%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 6 years

Fiscal year202520242023202220212020
Revenue——————
Net income-$12M-$11M-$22M-$28M-$30M-$16M
Free cash flow——-$16M-$19M-$13M-$8M
EPS (diluted)$-2.93$-2.86$-6.54$-8.30$-11.60$-6.70
Net margin——————
ROIC————-94.2%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 2 analysts is $44.00, 371% above the current price; targets range from $38.00 to $50.00; the consensus rating is “Strong buy”; expected EPS is $-2.45 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does MiNK Therapeutics pay a dividend?

Not currently.

Is MiNK Therapeutics a good stock to buy?

We do not give buy or sell advice. MiNK Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.